Correlation between clinical and molecular response after sequential CHOP and rituximab
| Clinical response after rituximab (% of 77 patients) . | Molecular response . | |||
|---|---|---|---|---|
| Bone marrow . | Peripheral blood . | |||
| PCR− (%) . | PCR+ (%) . | PCR− (%) . | PCR+ (%) . | |
| Complete 53 (69) | 40 (75) | 13 (25) | 47 (89) | 5 (11) |
| Partial 10 (13) | 3 (30) | 7 (70) | 3 (30) | 7 (70) |
| Rel/Prog 13 (17) | 2 (15) | 11 (85) | 4 (30) | 9 (70) |
| Too early 1 | — | — | — | — |
| Clinical response after rituximab (% of 77 patients) . | Molecular response . | |||
|---|---|---|---|---|
| Bone marrow . | Peripheral blood . | |||
| PCR− (%) . | PCR+ (%) . | PCR− (%) . | PCR+ (%) . | |
| Complete 53 (69) | 40 (75) | 13 (25) | 47 (89) | 5 (11) |
| Partial 10 (13) | 3 (30) | 7 (70) | 3 (30) | 7 (70) |
| Rel/Prog 13 (17) | 2 (15) | 11 (85) | 4 (30) | 9 (70) |
| Too early 1 | — | — | — | — |
The analysis was performed at the last molecular follow-up (wk +44 in 69 patients). For patients with evidence of an early disease relapse or progression, the last molecular follow-up was at wk +12 in 3 patients and at wk +28 in 1 patient.